Search results

  1. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

  2. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis

  3. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

  4. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)

  5. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced (unresectable or metastatic) melanoma

  6. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

    Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

  7. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

  8. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

    Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer